Zomedica Corp (ZOM): Net earnings per share (EPS TTM)

Symbol and logo of brand Zomedica Corporation (ZOM)

Zomedica Corp. proprietary technologies create significant barriers to entry, cementing clinic dependence on consumables. The "razor-and-blade" model provides substantial pricing power through rapid hormone analysis. However, an oligopolistic market and physician conservatism are slowing expansion. The TTM earnings per share trend illustrates business efficiency, while the value of -0.06 captures this metric at its current level.

ZOM (zomedica.com) Net earnings per share (EPS TTM) history from 07/04/2022 to 03/15/2025

ZOM (Zomedica Corp.): analytical breakdowns and indicator data

- stock price and consensus target price:
Basic company analysis:ZOM - Zomedica Corporation
Manufactured products of Zomedica Corporation

An objective valuation of Zomedica Corp. (ZOM) requires a deep analysis of the business's actual profitability. The eps_ttm_co metric measures net income allocated per share over a trailing twelve-month period, reflecting the actual efficiency of capital generation. By analyzing the EPS trend over the last 12 months, an investor can discern the balance between the market price and the asset's intrinsic value. Stable demand for veterinary diagnostics within a defensive sector supports the sustainability of these earnings, confirming the high quality of the issuer's capital.